C
Cassava Sciences, Inc. (SAVA)
NCM – Real Time Price. Currency in USD
2.38
+0.26 (12.26%)
At close: Mar 10, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.38
+0.26 (12.26%)
At close: Mar 10, 2026, 4:00 PM EDT
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
| Name | Position |
|---|---|
| Dr. Angélique Bordey Ph.D. | Senior Vice President of Neuroscience |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology |
| Dr. Joseph Hulihan M.D. | Chief Medical Officer |
| Jaren Landen | Chief Clinical Development Officer |
| Mr. Eric J. Schoen | Chief Financial Officer |
| Mr. Jack Moore Ph.D. | Senior Vice President of Clinical Development |
| Mr. Michael Zamloot | Senior Vice President of Technical Operations |
| Mr. R. Christopher Cook J.D. | Chief Operating & Legal Officer |
| Mr. Richard Jon Barry | CEO, President & Director |
| Ms. Freda Nassif | Chief Business Officer & Chief Commercial Officer |
| Date | Type | Document |
|---|---|---|
| 2025-12-23 | 8-K | sava20251222_8k.htm |
| 2025-12-22 | 8-K/A | sava20251219_8ka.htm |
| 2025-12-18 | 8-K | sava20251218_8k.htm |
| 2025-12-17 | 8-K | sava20251217_8k.htm |
| 2025-12-03 | 8-K | sava20251201_8k.htm |
| 2025-11-13 | S-3 | forms-3.htm |
| 2025-11-12 | 8-K | f8k_111225.htm |
| 2025-11-12 | 10-Q | sava20250930_10q.htm |
| 2025-10-24 | 8-K | sava20251024_8k.htm |
| 2025-10-22 | 8-K | sava20251020_8k.htm |